8-K: Knowles Corporation Exceeds Q2 2025 Revenue and Cash Flow Guidance, Projects Continued Growth

Knowles Corporation reported strong second-quarter 2025 financial results, with revenues and cash from operations surpassing guided ranges, driven by increased demand in Precision Devices and steady performance in MedTech and Specialty Audio.

Summary

• Q2 2025 revenues from continuing operations increased 8% year-over-year to $145.9 million, exceeding the high-end of the guided range.
• Net cash from operations was $36.4 million, also exceeding the high-end of the guided range.
• Non-GAAP diluted EPS from continuing operations was $0.24, above the mid-point of the guided range.
• Repurchased $30 million of shares in the second quarter of 2025.
• Precision Devices segment revenue increased 5.9% year-over-year to $78.5 million, with Adjusted EBITDA margins up 140 basis points to 20.8%.
• MedTech & Specialty Audio segment revenue grew 10.3% year-over-year to $67.4 million, with Adjusted EBITDA margins at 42.0%.
• Q3 2025 guidance projects revenues from continuing operations between $144 million and $154 million, and non-GAAP diluted EPS between $0.29 and $0.33.

Sentiment

Score: 8

Explanation: The company reported strong financial results for Q2 2025, exceeding guidance for revenue, cash from operations, and non-GAAP EPS. Management expressed confidence in continued growth and the strategic positioning of the business in high-growth markets like Medtech, Defense, and Industrial. Share repurchases further indicate financial strength and commitment to shareholder value, contributing to a very positive outlook.

Positives

• Q2 2025 revenues from continuing operations of $145.9 million exceeded the high-end of the guided range.
• Net cash from operations of $36.4 million exceeded the high-end of the guided range.
• Non-GAAP diluted EPS of $0.24 was above the mid-point of the guided range.
• Repurchased $30 million of shares in Q2 2025, demonstrating strong cash generation and commitment to shareholder value.
• Increased order activity and backlog in the Precision Devices segment across a broad range of end markets including Medtech, Defense, and Industrial.
• The MedTech and Specialty Audio business continues to perform at expectations, showing 10.3% year-over-year revenue growth.
• Expect continued sequential and year-over-year growth in the third quarter and throughout the remainder of 2025.
• Strong secular growth trends in Medtech, Defense, and Industrial markets, along with an expanding portfolio of differentiated products, position the company for year-over-year revenue growth beyond 2025.
• Adjusted free cash flow for Q2 2025 was $39.6 million, a significant increase from $23.2 million in Q2 2024.
• The net debt leverage ratio is low at 0.7x, indicating a healthy financial position.

Negatives

• MedTech & Specialty Audio Adjusted EBITDA margins were down 240 basis points year-over-year to 42.0%, driven by unfavorable product mix.
• Precision Devices Adjusted EBITDA margins were partially offset by higher scrap cost and factory inefficiencies as Specialty Film product lines ramp.
• GAAP diluted earnings per share from continuing operations was $0.09 in Q2 2025, significantly lower than non-GAAP EPS due to various adjustments including stock-based compensation, intangibles amortization, and impairment charges.
• Cash and cash equivalents decreased from $130.1 million at December 31, 2024, to $103.2 million at June 30, 2025.

Risks

• Inability to achieve some or all of the strategic and financial benefits expected from the CMM divestiture.
• Fluctuations in the stock's market price and in operating results and cash flows.
• Ability to prevent or identify quality issues in products or to promptly remedy any such issues.
• Risks associated with increasing inventories in advance of anticipated orders by customers.
• Global economic instability, including due to inflation, rising interest rates, pandemics, public health crises, or geopolitical uncertainties.
• Impact of changes to laws and regulations that affect the company's ability to offer products or services to customers in different regions.
• Ability to achieve reductions in operating expenses.
• Ability to qualify products and facilities with customers.
• Ability to obtain, enforce, defend, or monetize intellectual property rights.
• Disruption caused by a cybersecurity incident, including a cyber-attack, cyber breach, theft, or other unauthorized access.
• Increases in the costs of critical raw materials and components, and their availability.
• Challenges in managing new product ramps and introductions for customers.
• Dependence on a limited number of large customers and the ability to maintain and expand existing relationships with leading OEMs.
• Increasing competition and new entrants in the market for products.
• Ability to develop new or enhanced products or technologies in a timely manner that achieve market acceptance.
• Escalating international trade tensions, new or increased tariffs, and trade wars among countries.
• Financial risks, including risks relating to currency fluctuations, credit risks, and fluctuations in the market value of the company.
• A sustained decline in stock price and market capitalization may result in the impairment of certain intangible or long-lived assets.
• Market risk associated with fluctuations in commodity prices, particularly for various precious metals used in manufacturing operations.
• Changes in tax laws, changes in tax rates, and exposure to additional tax liabilities.

Future Outlook

For Q3 2025, Knowles Corporation expects revenues from continuing operations to be between $144 million and $154 million. Non-GAAP diluted earnings per share from continuing operations are projected to be between $0.29 and $0.33, and net cash provided by operating activities is anticipated to be between $20 million and $30 million. The company also expects full-year 2025 Adjusted EBITDA margins for MedTech and Specialty Audio to be in the low 40% range, and anticipates year-over-year revenue growth beyond 2025.

Management Comments

• "We closed the second quarter of 2025 with revenues and cash provided by operating activities exceeding the high-end of our guided range and non-GAAP diluted EPS from continuing operations above the mid-point of our guided range."
• "Our cash generated by operating activities in the quarter was strong, allowing us to repurchase $30 million in shares."
• "We continue to see increased order activity and backlog in our Precision Devices segment across a broad range of our end markets while the MedTech and Specialty Audio business continues to perform at expectations."
• "I expect continued growth sequentially and year over year in the third quarter and throughout the remainder of 2025."
• "Our current portfolio of businesses has a proven record of financial success in growing end markets. The most recent quarterly results demonstrate the potential for higher organic growth and margins."
• "Strong secular growth trends in Medtech, Defense, and Industrial markets along with an expanding portfolio of differentiated products positions Knowles for year over year revenue growth beyond 2025."
• "The momentum and strength of the business gives me confidence in our ability to continue to drive value for our shareholders."

Industry Context

Knowles Corporation's strong performance, particularly in its Precision Devices segment, aligns with robust demand in Medtech, Defense, and Industrial markets. The company's focus on high-performance components for these specialized sectors positions it to capitalize on secular growth trends, differentiating it from broader consumer electronics markets. The MedTech and Specialty Audio segment's consistent performance further underscores the stability derived from specialized, high-value applications, indicating a resilient business model within its niche industries.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, exceeding guidance, share repurchases, and a positive future outlook, potentially leading to increased share value.
• Employees: Positive impact from continued business growth and stability, though the filing mentions a restructuring program in forward-looking statements, specific employee impacts are not detailed as a current event.
• Customers: Positive impact from increased order activity and backlog, suggesting strong demand and continued product development and supply.
• Suppliers: Potential positive impact from increased production volumes and order activity, indicating sustained demand for raw materials and components.

Next Steps

• Quarterly financial conference call and webcast held on July 24, 2025.
• Continued sequential and year-over-year growth expected in Q3 2025 and throughout the remainder of 2025.
• Full year 2025 Adjusted EBITDA margins for MedTech and Specialty Audio expected to be in the low 40% range.
• Positioned for year-over-year revenue growth beyond 2025.

Key Dates

Recommendation

The company delivered a robust second quarter, surpassing its own guidance across key financial metrics including revenue, cash from operations, and non-GAAP EPS. Management's commentary indicates strong demand, particularly in the Precision Devices segment across Medtech, Defense, and Industrial markets, which are characterized by secular growth trends. The outlook for Q3 2025 projects continued growth, and the company's strategic positioning with differentiated products supports revenue growth beyond 2025. Furthermore, the company's strong cash generation enabled a significant share repurchase program, and its net debt leverage ratio is very healthy at 0.7x. These factors collectively point to strong operational momentum, financial discipline, and a positive trajectory, making it an attractive investment.

Keywords

Specialty Electronic Components, Medtech, Defense, Industrial, High Performance Capacitors, RF Filters, Advanced Medtech Microphones, Balanced Armature Speakers, Financial Results, Earnings, Q2 2025, Knowles Corporation, KN, NYSE, Semiconductor, Electronic Manufacturing